##### Table of Contents

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549



---

FORM 10-Q



---



|x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ---------------------------------------------------------------------------------------

FOR THE QUARTERLY PERIOD ENDED March 31, 2006

OR



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------------

FOR THE TRANSITION PERIOD FROM  TO
.

COMMISSION FILE NUMBER: 0-31265



---

TELIK, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)



---



|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|DELAWARE                                                       |  | 93-0987903                          
|(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION) |  | (I.R.S. EMPLOYER IDENTIFICATION NO.)

3165 PORTER DRIVE, PALO ALTO, CA 94304

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)

REGISTRANTS TELEPHONE NUMBER, INCLUDING AREA CODE: (650) 845-7700



---

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: NONE

SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:

COMMON STOCK $0.01 PAR VALUE

(TITLE OF CLASS)



---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90
days.    Yes  x    No ̈

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer
and large accelerated filer in Rule 12b-2 of the Exchange Act).

Large accelerated filer  x                                Accelerated
Filer ̈Non-accelerated Filer ̈

Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).    Yes ̈No  x

Indicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest
practicable date.



|                                    |  |                                                 
|----------------------------------- |  | ------------------------------------------------
|Class: Common Stock $0.01 par value |  | Outstanding at April 28, 2006: 52,253,223 shares



---



---

##### Table of Contents

TELIK, INC.

INDEX



|                              |  |                                                                                       |  |     
|----------------------------- |  | ------------------------------------------------------------------------------------- |  | ----
|                              |  |                                                                                       |  | Page
|PART I. FINANCIAL INFORMATION |  |                                                                                      
|                              |  |                                                                                      
|Item 1:                       |  | Financial Statements (Unaudited)                                                      |  |     
|                              |  |                                                                                      
|                              |  | Condensed Balance Sheets at March 31, 2006 and December 31, 2005                      |  | 3   
|                              |  |                                                                                      
|                              |  | Condensed Statements of Operations for the three months ended March 31, 2006 and 2005 |  | 4   
|                              |  |                                                                                      
|                              |  | Condensed Statements of Cash Flows for the three months ended March 31, 2006 and 2005 |  | 5   
|                              |  |                                                                                      
|                              |  | Notes to Condensed Financial Statements                                               |  | 6   
|                              |  |                                                                                      
|Item 2:                       |  | Managements Discussion and Analysis of Financial Condition and Results of Operations |  | 12  
|                              |  |                                                                                      
|Item 3:                       |  | Quantitative and Qualitative Disclosures About Market Risk                            |  | 20  
|                              |  |                                                                                      
|Item 4:                       |  | Controls and Procedures                                                               |  | 21  
|                              | 
|PART II. OTHER INFORMATION    |  |                                                                                      
|                              |  |                                                                                      
|Item 1A:                      |  | Risk Factors                                                                          |  | 22  
|                              |  |                                                                                      
|Item 6:                       |  | Exhibits                                                                              |  | 32  
|                              | 
|SIGNATURES                    |  | 33                                                                                   



2



---

##### Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

TELIK, INC.

CONDENSED BALANCE SHEETS

(In thousands, except share and per share data)



|                                                                                                                                                              |             |               |          |          |                  |   |          |  
|------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------- | ------------- | -------- | -------- | ---------------- | - | -------- | -
|                                                                                                                                                              |             | March 31,2006 |          |          | December 31,2005 |  
|                                                                                                                                                              | (Unaudited) |               |          | (Note 1) |                 
|Assets                                                                                                                                                        |             |               |          |          |                  |   |          |  
|Current assets:                                                                                                                                               |             |               |          |          |                  |   |          |  
|Cash and cash equivalents                                                                                                                                     |             | $             | 98,428   |          |                  | $ | 127,971  |  
|Short-term investments                                                                                                                                        |             |               | 86,907   |          |                  |   | 75,876   |  
|Other receivables                                                                                                                                             |             |               | 571      |          |                  |   | 687      |  
|Prepaids and other current assets                                                                                                                             |             |               | 1,424    |          |                  |   | 1,418    |  
|                                                                                                                                                              |             |               |          |          |                  |   |          |  
|Total current assets                                                                                                                                          |             |               | 187,330  |          |                  |   | 205,952  |  
|Property and equipment, net                                                                                                                                   |             |               | 4,740    |          |                  |   | 5,042    |  
|Restricted investments                                                                                                                                        |             |               | 1,796    |          |                  |   | 1,796    |  
|Other assets                                                                                                                                                  |             |               | 463      |          |                  |   | 556      |  
|                                                                                                                                                              |             |               |          |          |                  |   |          |  
|Total assets                                                                                                                                                  |             | $             | 194,329  |          |                  | $ | 213,346  |  
|                                                                                                                                                              |             |               |          |          |                  |   |          |  
|Liabilities and Stockholders Equity                                                                                                                          |             |               |          |          |                  |   |          |  
|Current liabilities:                                                                                                                                          |             |               |          |          |                  |   |          |  
|Accounts payable                                                                                                                                              |             | $             | 1,961    |          |                  | $ | 1,269    |  
|Accrued clinical trials                                                                                                                                       |             |               | 8,854    |          |                  |   | 11,509   |  
|Accrued compensation                                                                                                                                          |             |               | 1,857    |          |                  |   | 4,049    |  
|Accrued liabilities                                                                                                                                           |             |               | 990      |          |                  |   | 948      |  
|Current portion of capital leases and equipment loans                                                                                                         |             |               | 659      |          |                  |   | 901      |  
|                                                                                                                                                              |             |               |          |          |                  |   |          |  
|Total current liabilities                                                                                                                                     |             |               | 14,321   |          |                  |   | 18,676   |  
|                                                                                                                                                              |             |              
|Non-current portion of capital leases and equipment loans                                                                                                     |             |               | 66       |          |                  |   | 145      |  
|                                                                                                                                                              |             |              
|Commitments                                                                                                                                                   |             |               |          |          |                  |   |          |  
|Stockholders equity:                                                                                                                                         |             |               |          |          |                  |   |          |  
|Common stock, $0.01 par value, 100,000,000 shares authorized; shares issued and outstanding: 52,253,223 at March 31, 2006 and 52,038,850
at December 31, 2005 |             |               | 523      |          |                  |   | 520      |  
|Additional paid-in capital                                                                                                                                    |             |               | 513,091  |          |                  |   | 507,585  |  
|Accumulated other comprehensive loss                                                                                                                          |             |               | (306     | )        |                  |   | (290     | )
|Accumulated deficit                                                                                                                                           |             |               | (333,366 | )        |                  |   | (313,290 | )
|                                                                                                                                                              |             |               |          |          |                  |   |          |  
|Total stockholders equity                                                                                                                                    |             |               | 179,942  |          |                  |   | 194,525  |  
|                                                                                                                                                              |             |               |          |          |                  |   |          |  
|Total liabilities and stockholders equity                                                                                                                    |             | $             | 194,329  |          |                  | $ | 213,346  |  
|                                                                                                                                                              |             |               |          |          |                  |   |          |  

See accompanying Notes to Condensed Financial Statements.



3



---

##### Table of Contents

TELIK, INC.

CONDENSED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)



|                                                              |      |                             |         |      |  |   |         |  
|------------------------------------------------------------- | ---- | --------------------------- | ------- | ---- |  | - | ------- | -
|                                                              |      | Three Months EndedMarch 31, |        
|                                                              | 2006 |                             |         | 2005 | 
|Contract revenue from collaborations                          |      | $                           |        |      |  | $ | 19      |  
|                                                              |      |                            
|Operating costs and expenses:                                 |      |                             |         |      |  |   |         |  
|Research and development                                      |      |                             | 17,658  |      |  |   | 19,145  |  
|General and administrative                                    |      |                             | 4,509   |      |  |   | 2,633   |  
|                                                              |      |                             |         |      |  |   |         |  
|Total operating costs and expenses                            |      |                             | 22,167  |      |  |   | 21,778  |  
|                                                              |      |                             |         |      |  |   |         |  
|Loss from operations                                          |      |                             | (22,167 | )    |  |   | (21,759 | )
|                                                              |      |                            
|Interest income                                               |      |                             | 2,107   |      |  |   | 1,377   |  
|Interest expense                                              |      |                             | (16     | )    |  |   | (42     | )
|                                                              |      |                             |         |      |  |   |         |  
|Net loss                                                      |      | $                           | (20,076 | )    |  | $ | (20,424 | )
|                                                              |      |                             |         |      |  |   |         |  
|Basic and diluted net loss per share                          |      | $                           | (0.38   | )    |  | $ | (0.42   | )
|                                                              |      |                             |         |      |  |   |         |  
|Shares used to calculate basic and diluted net loss per share |      |                             | 52,162  |      |  |   | 48,966  |  
|                                                              |      |                             |         |      |  |   |         |  

See accompanying Notes to Condensed Financial Statements.



4



---

##### Table of Contents

TELIK, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)



|                                                                            |      |                             |         |      |  |   |         |  
|--------------------------------------------------------------------------- | ---- | --------------------------- | ------- | ---- |  | - | ------- | -
|                                                                            |      | Three Months EndedMarch 31, |        
|                                                                            | 2006 |                             |         | 2005 | 
|Cash flows from operating activities:                                       |      |                             |         |      |  |   |         |  
|Net loss                                                                    |      | $                           | (20,076 | )    |  | $ | (20,424 | )
|Adjustments to reconcile net loss to net cash used in operating activities: |      |                             |         |      |  |   |         |  
|Depreciation and amortization                                               |      |                             | 442     |      |  |   | 363     |  
|Share-based compensation expense                                            |      |                             | 3,623   |      |  |   |        |  
|Changes in assets and liabilities:                                          |      |                             |         |      |  |   |         |  
|Other receivables                                                           |      |                             | 116     |      |  |   | (159    | )
|Prepaid expenses and other current assets                                   |      |                             | (6      | )    |  |   | 22      |  
|Accounts payable                                                            |      |                             | 692     |      |  |   | 806     |  
|Accrued clinical trials, compensation and other liabilities                 |      |                             | (4,712  | )    |  |   | (1,389  | )
|Deferred revenue                                                            |      |                             |        |      |  |   | (19     | )
|                                                                            |      |                             |         |      |  |   |         |  
|Net cash used in operating activities                                       |      |                             | (19,921 | )    |  |   | (20,800 | )
|                                                                            |      |                             |         |      |  |   |         |  
|Cash flows from investing activities:                                       |      |                             |         |      |  |   |         |  
|Purchases of investments                                                    |      |                             | (19,042 | )    |  |   | (63,753 | )
|Sales of investments                                                        |      |                             | 3,000   |      |  |   | 16,550  |  
|Maturities of investments                                                   |      |                             | 4,995   |      |  |   | 13,037  |  
|Purchases of property and equipment                                         |      |                             | (140    | )    |  |   | (342    | )
|                                                                            |      |                             |         |      |  |   |         |  
|Net cash used in investing activities                                       |      |                             | (11,187 | )    |  |   | (34,508 | )
|                                                                            |      |                             |         |      |  |   |         |  
|Cash flows from financing activities:                                       |      |                             |         |      |  |   |         |  
|Principal payments under capital leases and equipment loans                 |      |                             | (321    | )    |  |   | (326    | )
|Proceeds from issuance of common stock                                      |      |                             | 1,886   |      |  |   | 143,038 |  
|                                                                            |      |                             |         |      |  |   |         |  
|Net cash provided by financing activities                                   |      |                             | 1,565   |      |  |   | 142,712 |  
|                                                                            |      |                             |         |      |  |   |         |  
|Net (decrease) increase in cash and cash equivalents                        |      |                             | (29,543 | )    |  |   | 87,404  |  
|Cash and cash equivalents at beginning of period                            |      |                             | 127,971 |      |  |   | 56,221  |  
|                                                                            |      |                             |         |      |  |   |         |  
|Cash and cash equivalents at end of period                                  |      | $                           | 98,428  |      |  | $ | 143,625 |  
|                                                                            |      |                             |         |      |  |   |         |  
|Supplementary information:                                                  |      |                             |         |      |  |   |         |  
|Interest paid                                                               |      | $                           | 16      |      |  | $ | 42      |  

See accompanying Notes to Condensed Financial Statements.



5



---

##### Table of Contents

TELIK, INC.

Notes to Condensed Financial Statements

(Unaudited)

1. Basis of presentation and summary
of significant accounting policies

We have prepared the accompanying financial statements in accordance with U.S. generally accepted
accounting principles , or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Exchange Act. Accordingly, they do not include all of the information and footnotes required by GAAP
for complete financial statements. We believe all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included herein. Operating results for the three months ended March 31, 2006
are not necessarily indicative of the results that may be expected for the year ending December 31, 2006 or any other period. The balance sheet at December 31, 2005 has been derived from the audited financial statements at that date. You
should read these financial statements and notes in conjunction with our audited financial statements for the year ended December 31, 2005, which are included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission
on March 3, 2006.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those
estimates.

Share-based employee compensation

In December 2004, the Financial Accounting Standards Board (FASB) issued Statement of Accounting Standards No. 123R Share-Based Payment (SFAS 123(R)). We adopted the provisions of SFAS 123(R) on
January 1, 2006. Accordingly, compensation cost for all share-based awards to employees is measured based on the grant date fair value of those awards and recognized over the period during which the employee is required to perform service in
exchange for the award (generally over the vesting period of the award). We have no awards with market or performance conditions. Effective January 1, 2006, SFAS 123(R) supersedes our previous accounting under Accounting Principles Board
Opinion No. 25, Accounting for Stock Issued to Employees(APB 25). In March 2005, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 107 (SAB 107) relating to SFAS
123(R). We have applied the provisions of SAB 107 in our adoption of SFAS 123(R).

In November 2005, the FASB issued FASB Staff Position
No. FAS123(R)-3, Transition Election Related to Accounting for the Tax Effects of Share-Based Payment Awards (FAS 123(R)-3). We have adopted the simplified method to calculate the beginning balance of the additional
paid-in-capital (or APIC) pool of the excess tax benefit, and to determine the subsequent impact on the APIC pool and Condensed Statements of Cash Flows of the tax effects of employee stock-based compensation awards that were outstanding
upon our adoption of SFAS 123(R).

We adopted SFAS 123(R) using the modified prospective transition method, which provides for certain
changes to the method for valuing share-based compensation. The valuation provisions of SFAS 123(R) apply to new awards and to awards that are outstanding at the effective date and subsequently modified or cancelled. Estimated compensation expense
for awards outstanding at the effective date will be recognized over the remaining service period using the compensation cost calculated for pro forma disclosure purposes under FASB Statement No. 123, Accounting for Stock-Based
Compensation (SFAS 123). Our financial statements as of and for the quarter ended March 31, 2006 reflect the impact of SFAS 123(R). In accordance with the modified prospective transition method, our financial statements for
prior periods were not restated to reflect, and do not include, any share-based compensation expense associated with employee stock awards.

Share-based compensation expense is based on the fair value of that portion of employee stock options that is ultimately expected to vest during the period. Share-based compensation expense recognized in our



6



---

##### Table of Contents

statement of operations for the first quarter of fiscal 2006 included compensation expense for share-based awards granted prior to, but not yet vested as of,
December 31, 2005, based on the grant date fair value estimated in accordance with the pro forma provisions of SFAS 123, and share-based awards granted subsequent to December 31, 2005 based on the grant date fair value estimated in
accordance with SFAS 123(R). For stock options granted after January 1, 2006, the fair value of each award is amortized using the straight-line single-option method. For share awards granted prior to 2006, the fair value of each award is
amortized using the accelerated multiple-option valuation method prescribed by SFAS 123. Share-based compensation expense is based on awards ultimately expected to vest, therefore, it has been reduced for estimated forfeitures. SFAS 123(R) requires
forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures were estimated to be approximately 9% in the first quarter of fiscal 2006 based on our
historical experience. In our pro forma information required under SFAS 123 for the periods prior to 2006, we accounted for forfeitures as they occurred.

Total estimated share-based compensation expense, related to all of our share-based awards, recognized under SFAS 123(R) was comprised of the following:



|                                                                    |  |                                   |       |  
|------------------------------------------------------------------- |  | --------------------------------- | ----- | -
|(In thousands except per share amount)                              |  | Three Months Ended March 31, 2006 |      
|Research and development                                            |  | $                                 | 2,275 |  
|General and administrative                                          |  |                                   | 1,348 |  
|                                                                    |  |                                   |       |  
|Share-based compensation expense before taxes                       |  |                                   | 3,623 |  
|Related income tax benefits                                         |  |                                   |      |  
|Effect of share-based compensation expense on net loss              |  | $                                 | 3,623 |  
|                                                                    |  |                                   |       |  
|Share-based compensation expense per basic and diluted common share |  | $                                 | (0.07 | )
|                                                                    |  |                                   |       |  

Since we have a net operating loss carryforward as of March 31, 2006, no excess tax benefits
for the tax deductions related to share-based compensation expense were recognized in our statement of operations. Additionally, no incremental tax benefits were recognized from stock options exercised in the quarter ended March 31, 2006, which
would have resulted in a reclassification to reduce net cash provided by operating activities with an offsetting increase in net cash provided by financing activities. No share-based compensation expense was recognized during the quarter ended
March 31, 2005. As of March 31, 2006, $22.0 million of total unrecognized compensation costs, net of forfeitures, related to non-vested awards is expected to be recognized over a weighted average period of 2.52 years.

We grant stock options to our employees, outside directors and consultants and provide employees the right to purchase our stock pursuant to stockholder
approved stock option and employee stock purchase plans. As of March 31, 2006, we had four equity incentive plans (the Plans): the 2000 Equity Incentive Plan, the 2000 Non-Employee Directors Stock Option Plan, the 1996 Stock
Option Plan and the 2000 Employee Stock Purchase Plan. Under the Plans we had an aggregate of 12,050,526 shares of our common stock reserved for issuance as of March 31, 2006. Of those shares, 8,994,903 shares were subject to outstanding
options and 3,055,623 shares were available for future grants of share-based awards.

2000 Equity Incentive Plan. Options granted
under the 2000 Equity Incentive Plan (the 2000 Plan)may be either incentive stock options (ISOs) or nonstatutory stock options (NSOs). For ISOs and NSOs, the option price shall be at least 100% and 85%,
respectively, of the closing price of our common stock on the date of the grant, or in the event there is no public market for our common stock, of the fair value on the date of the grant, as determined by our board of directors. Options generally
vest over a period of four years from the date of grant, one fourth vesting one year after the date of the grant and the balance vesting monthly thereafter. Options granted under the 2000 Plan expire no later than 10 years from the date of grant.

2000 Non-Employee Directors Stock Option Plan. Under the 2000 Non-Employee Directors Stock Option Plan (the
Directors Plan), each non-employee director who becomes a director of Telik is entitled to



7



---

##### Table of Contents

receive nonstatutory stock options grants. The exercise price of options under the Directors Plan will be equal to the fair market value of the common
stock on the date of grant. The maximum term of the options granted under the Directors Plan is 10 years. All grants under the Directors Plan will vest over a period of four years from date of grant, one fourth vesting one year after the
date of the grant and thereafter the balance vesting monthly.

1996 Stock Option Plan. The 1996 Stock Option Plan (the 1996
Plan) was adopted in April 1996. The terms are similar to the 2000 Plan. The 1996 Plan was terminated upon our initial public offering on August 11, 2000, and no new options can be granted under this plan. The termination of the 1996 Plan
had no effect upon outstanding options under the plan.

2000 Employee Stock Purchase Plan. Our 2000 Employee Stock Purchase Plan
(the Purchase Plan) permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which the stock is purchased is equal to the lower of 85% of the fair market
value of the common stock on the first day of the offering or 85% of the fair market value of our common stock on the purchase date. Through the end of March 31, 2006, we have issued a total of 440,187 shares under the Purchase Plan, and
709,813 shares remain available for future issuance.

The fair value of each option award is estimated on the date of grant using a
Black-Scholes-Merton option pricing model (Black-Scholes model) that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of our common stock and other factors. The expected term of
options granted is based on the simplified method in accordance with the SECs Staff Accounting Bulletin No. 107 (SAB 107) as our historical share option exercise experience does not provide a reasonable basis for estimation.
The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. Assumptions used in the Black-Scholes model were as follows:



|                         |                    |                                   |   |                     |              
|------------------------ | ------------------ | --------------------------------- | - | ------------------- | -------------
|                         |                    | Three Months Ended March 31, 2006
|                         | Stock Option Plans |                                   |   | Stock Purchase Plan
|Expected volatility      |                    | 63.1                              | % |                     | 35.6%  38.8%
|Risk-free interest rate  |                    | 4.56                              | % |                     | 4.58%  4.74%
|Expected life (in years) |                    | 6.08                              |   |                     | 0.5  1.5    
|Expected dividend yield  |                    |                                  |   |                     |             

A summary of option activity under our plans as of March 31, 2006 is presented below.



|                                 |  |                 |   |  |                                       |       |                                                    |      |                                       |   |     
|-------------------------------- |  | --------------- | - |  | ------------------------------------- | ----- | -------------------------------------------------- | ---- | ------------------------------------- | - | ----
|                                 |  | Number ofshares |   |  | Weightedaverageexerciseprice pershare |       | Weightedaverageremainingcontractualterm (in years) |      | Aggregateintrinsicvalue (in millions)
|Outstanding at December 31, 2005 |  | 8,465,649       |   |  | $                                     | 13.55 |                                                    |      |                                       |   |     
|Granted                          |  | 737,500         |   |  | $                                     | 20.12 |                                                    |      |                                       |   |     
|Exercised                        |  | (173,298        | ) |  | $                                     | 7.71  |                                                    |      |                                       |   |     
|Forfeited or expired             |  | (34,948         | ) |  | $                                     | 19.57 |                                                    |      |                                       |   |     
|                                 |  |                 |   |  |                                       |       |                                                    |      |                                       |   |     
|Outstanding at March 31, 2006    |  | 8,994,903       |   |  | $                                     | 14.17 |                                                    | 6.93 |                                       | $ | 53.0
|                                 |  |                 |   |  |                                       |       |                                                    |      |                                       |   |     
|Exercisable at March 31, 2006    |  | 5,089,704       |   |  | $                                     | 10.61 |                                                    | 5.55 |                                       | $ | 47.6

The weighted average grant-date fair value of options granted during the quarters ended
March 31, 2006 and 2005 were $12.50 per share and $11.07 per share. The total intrinsic value of options exercised during the quarters ended March 31, 2006 and 2005 were $2,070,622 and $214,813.



8



---

##### Table of Contents

A summary of the status of our non-vested stock options as of March 31, 2006 is presented below.



|                                |  |                 |   |  |                                                  |      
|------------------------------- |  | --------------- | - |  | ------------------------------------------------ | -----
|                                |  | Number ofshares |   |  | Weighted average grant-date fair value per share
|Non-vested at December 31, 2005 |  | 3,891,859       |   |  | $                                                | 11.40
|Granted                         |  | 737,500         |   |  | $                                                | 12.50
|Vested                          |  | (689,212        | ) |  | $                                                | 13.05
|Forfeited or expired            |  | (34,948         | ) |  | $                                                | 12.11
|                                |  |                 |   |  |                                                  |      
|Non-vested at March 31, 2006    |  | 3,905,199       |   |  | $                                                | 11.31
|                                |  |                 |   |  |                                                  |      

The total fair value of shares vested during the quarters ended March 31, 2006 and 2005 were
$9.0 million and $3.7 million.

Pro Forma Information under SFAS 123. Prior to January 1, 2006, we accounted for share-based
awards to employees using the intrinsic value method in accordance with APB 25 and related interpretations and provided the required pro forma disclosures of SFAS 123. Under the intrinsic value method, no share-based compensation expense was
recognized in our statement of operations for share-based awards to employees, because the exercise price of our stock options granted to employees equaled the fair market value of the underlying stock at the date of grant. The following table
summarizes the pro forma effect on our net loss and per share data if we had applied the fair value recognition provisions of SFAS 123 to share-based employee compensation.



|                                                                                                         |  |                                   |         |  
|-------------------------------------------------------------------------------------------------------- |  | --------------------------------- | ------- | -
|(in thousands except per share amounts)                                                                  |  | Three Months Ended March 31, 2005 |        
|Net loss  as reported                                                                                   |  | $                                 | (20,424 | )
|Add: Stock-based employee compensation included in reported net loss                                     |  |                                   |        |  
|Deduct: Total stock-based employee compensation expense under the fair value based method for all awards |  |                                   | (4,780  | )
|                                                                                                         |  |                                   |         |  
|Net loss  pro forma                                                                                     |  | $                                 | (25,204 | )
|                                                                                                         |  |                                   |         |  
|Basic and diluted net loss per share  as reported                                                       |  | $                                 | (0.42   | )
|                                                                                                         |  |                                   |         |  
|Basic and diluted net loss per share  pro forma                                                         |  | $                                 | (0.51   | )
|                                                                                                         |  |                                   |         |  

For employee stock options granted during the quarter ended March 31, 2005, we determined pro
forma compensation expense using the Black-Scholes model and the following assumptions: (1) expected volatility of 67.9%, (2) expected term of 5.0 years, (3) risk-free interest rate of 4.0% and (4) expected dividend yield of
0%. The weighted average fair value of options granted during the quarter ended March 31, 2005 was $11.07 per share. For common stock purchased by our employees through our employee stock purchase plan the following assumptions were used:
(1) expected volatility of 70.4%, (2) expected term of 1.39 years, (3) risk-free interest rate of 2.69% and (4) expected dividend yield of 0%.

We account for stock options granted to non-employees in accordance with Emerging Issues Task Force No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in
Conjunction with Selling, Goods or Services, (EITF 96-18). Under EITF 96-18, we determine the fair value of the stock options granted as either the fair value of the consideration received or the fair value of the equity
instruments issued, whichever is more reliably measurable.



9



---

##### Table of Contents

2. Comprehensive loss

Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) includes changes in unrealized gains (losses) on investments. Comprehensive loss for the three
months ended March 31, 2006 and 2005 were as follows:



|                                            |                |                             |         |      |  |   |         |  
|------------------------------------------- | -------------- | --------------------------- | ------- | ---- |  | - | ------- | -
|                                            |                | Three Months EndedMarch 31, |        
|                                            | 2006           |                             |         | 2005 | 
|                                            | (In thousands) |                            
|Net loss                                    |                | $                           | (20,076 | )    |  | $ | (20,424 | )
|Changes in unrealized losses on investments |                |                             | (16     | )    |  |   | (207    | )
|                                            |                |                             |         |      |  |   |         |  
|Comprehensive loss                          |                | $                           | (20,092 | )    |  | $ | (20,631 | )
|                                            |                |                             |         |      |  |   |         |  

3. Basic and diluted net loss per share

We have computed net loss per share according to SFAS No. 128, Earnings Per Share, which requires disclosure of basic and diluted
earnings per share. Basic earnings per share excludes any dilutive effects of options, shares subject to repurchase, warrants and convertible securities. Diluted earnings per share includes the impact of potentially dilutive securities.

Outstanding options to purchase an aggregate of 8,994,903 and 7,960,004 shares of our common stock for the three months ending March 31, 2006 and
2005 were excluded from diluted net loss per common share calculations because inclusion of such options would have an anti-dilutive effect on losses in these periods.

4. Cash, cash equivalents, investments and restricted investments

The following is a summary of
cash and cash equivalents, investments and restricted investments:



|                            |                |                |                      |  |                       |    |  |                     |      |   |  |   |        
|--------------------------- | -------------- | -------------- | -------------------- |  | --------------------- | -- |  | ------------------- | ---- | - |  | - | -------
|                            |                | March 31, 2006
|                            | AmortizedCosts |                | GrossUnrealizedGains |  | GrossUnrealizedLosses |    |  | EstimatedFair Value
|                            | (in thousands)
|Certificate of deposits     |                | $              | 1,796                |  | $                     |   |  | $                   |     |   |  | $ | 1,796  
|Corporate notes             |                |                | 36,100               |  |                       |   |  |                     |     |   |  |   | 36,100 
|Commercial paper            |                |                | 87,716               |  |                       | 18 |  |                     |     |   |  |   | 87,734 
|Government notes            |                |                | 53,620               |  |                       |   |  |                     | (324 | ) |  |   | 53,296 
|Cash and money market funds |                |                | 8,205                |  |                       |   |  |                     |     |   |  |   | 8,205  
|                            |                |                |                      |  |                       |    |  |                     |      |   |  |   |        
|Total                       |                | $              | 187,437              |  | $                     | 18 |  | $                   | (324 | ) |  | $ | 187,131
|                            |                |                |                      |  |                       |    |  |                     |      |   |  |   |        
|Reported as:                |                |                |                      |  |                       |    |  |                     |      |   |  |   |        
|Cash and cash equivalents   |                |                |                      |  |                       |    |  |                     |      |   |  | $ | 98,428 
|Short term investments      |                |                |                      |  |                       |    |  |                     |      |   |  |   | 86,907 
|Restricted investments      |                |                |                      |  |                       |    |  |                     |      |   |  |   | 1,796  
|                            |                |                |                      |  |                       |    |  |                     |      |   |  |   |        
|Total                       |                |                |                      |  |                       |    |  |                     |      |   |  | $ | 187,131
|                            |                |                |                      |  |                       |    |  |                     |      |   |  |   |        



10



---

##### Table of Contents

|                            |                |                   |                      |  |                       |    |  |                     |      |   |  |   |        
|--------------------------- | -------------- | ----------------- | -------------------- |  | --------------------- | -- |  | ------------------- | ---- | - |  | - | -------
|                            |                | December 31, 2005
|                            | AmortizedCosts |                   | GrossUnrealizedGains |  | GrossUnrealizedLosses |    |  | EstimatedFair Value
|                            | (in thousands)
|Certificate of deposits     |                | $                 | 1,796                |  | $                     |   |  | $                   |     |   |  | $ | 1,796  
|Corporate notes             |                |                   | 38,366               |  |                       |   |  |                     | (8   | ) |  |   | 38,358 
|Commercial paper            |                |                   | 113,289              |  |                       | 28 |  |                     |     |   |  |   | 113,317
|Government notes            |                |                   | 42,167               |  |                       |   |  |                     | (310 | ) |  |   | 41,857 
|Cash and money market funds |                |                   | 10,315               |  |                       |   |  |                     |     |   |  |   | 10,315 
|                            |                |                   |                      |  |                       |    |  |                     |      |   |  |   |        
|Total                       |                | $                 | 205,933              |  | $                     | 28 |  | $                   | (318 | ) |  | $ | 205,643
|                            |                |                   |                      |  |                       |    |  |                     |      |   |  |   |        
|Reported as:                |                |                   |                      |  |                       |    |  |                     |      |   |  |   |        
|Cash and cash equivalents   |                |                   |                      |  |                       |    |  |                     |      |   |  | $ | 127,971
|Short term investments      |                |                   |                      |  |                       |    |  |                     |      |   |  |   | 75,876 
|Restricted investments      |                |                   |                      |  |                       |    |  |                     |      |   |  |   | 1,796  
|                            |                |                   |                      |  |                       |    |  |                     |      |   |  |   |        
|Total                       |                |                   |                      |  |                       |    |  |                     |      |   |  | $ | 205,643
|                            |                |                   |                      |  |                       |    |  |                     |      |   |  |   |        

The net realized gains on sales of available-for-sale investments were not material for the three
months ended March 31, 2006 and 2005. Realized gains and losses were calculated based on the specific identification method.

The
following is a summary of the cost and estimated fair value of available-for-sale securities at March 31, 2006 and December 31, 2005, classified by stated maturity date of the security:



|                             |               |                |            |                   |               |         |            |   |         |  |   |        
|---------------------------- | ------------- | -------------- | ---------- | ----------------- | ------------- | ------- | ---------- | - | ------- |  | - | -------
|                             |               | March 31, 2006 |            | December 31, 2005
|                             | AmortizedCost |                | Fair Value |                   | AmortizedCost |         | Fair Value
|                             |               | (in thousands)
|Mature in less than one year |               | $              | 132,094    |                   | $             | 131,901 |            | $ | 153,713 |  | $ | 153,507
|Mature in one to three years |               |                | 17,842     |                   |               | 17,729  |            |   | 13,609  |  |   | 13,525 
|Mature in over three years   |               |                | 27,500     |                   |               | 27,500  |            |   | 26,500  |  |   | 26,500 
|                             |               |                |            |                   |               |         |            |   |         |  |   |        
|Total                        |               | $              | 177,436    |                   | $             | 177,130 |            | $ | 193,822 |  | $ | 193,532
|                             |               |                |            |                   |               |         |            |   |         |  |   |        

5. Property and equipment, net

Property and equipment consist of the following:



|                                               |                |               |        |   |                  |   |        |  
|---------------------------------------------- | -------------- | ------------- | ------ | - | ---------------- | - | ------ | -
|                                               |                | March 31,2006 |        |   | December 31,2005 |  
|                                               | (in thousands) |              
|Computer and lab equipment                     |                | $             | 7,207  |   |                  | $ | 7,079  |  
|Capitalized software                           |                |               | 547    |   |                  |   | 547    |  
|Office furniture and fixtures                  |                |               | 412    |   |                  |   | 410    |  
|Leasehold improvements                         |                |               | 3,226  |   |                  |   | 3,219  |  
|                                               |                |               |        |   |                  |   |        |  
|                                               |                |               | 11,392 |   |                  |   | 11,255 |  
|Less accumulated depreciation and amortization |                |               | (6,652 | ) |                  |   | (6,213 | )
|                                               |                |               |        |   |                  |   |        |  
|Property and equipment, net                    |                | $             | 4,740  |   |                  | $ | 5,042  |  
|                                               |                |               |        |   |                  |   |        |  



11



---

##### Table of Contents

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations

Special Note
Regarding Statements of Expected Future Performance

This Quarterly Report on Form 10-Q contains statements indicating expectations
about future performance and other forward-looking statements that involve risks and uncertainties. We usually use words such as may, will, should, expect, plan, anticipate,
believe, estimate, predict, future, intend, potential, or continue or the negative of these terms or similar expressions to identify forward-looking statements.
These statements appear throughout this Quarterly Report on Form 10-Q and are statements regarding our current intent, belief or expectation, primarily with respect to our operations and related industry developments. Examples of these statements
include, but are not limited to, statements regarding the following: the implications of positive interim results of our Phase 2 clinical trials, the progress of our research programs, including clinical testing, the extent to which our issued and
pending patents may protect our products and technology, our ability to identify new product candidates using TRAP technology (our proprietary Target-Related Affinity Profiling technology), the potential of such product candidates to lead to the
development of safer or more effective therapies, our ability to develop the technology derived from our collaborations, our anticipated timing for filing additional Investigational New Drug applications, or INDs, with the United States Food and
Drug Administration, or FDA, or for the initiation or completion of Phase 1, Phase 2 or Phase 3 clinical trials for any of our product candidates, our future operating expenses, our future losses, our future expenditures for research and development
and the sufficiency of our cash resources. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form 10-Q. Our actual results could differ materially from those
anticipated in these forward-looking statements for many reasons, including the risks faced by us and described in Part II, Item 1A of this Quarterly Report on Form 10-Q.

The following discussion and analysis should be read in conjunction with the unaudited financial statements and notes thereto included in Part I,
Item 1 of this Quarterly Report on Form 10-Q and with the financial statements and notes thereto and Managements Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the
year ended December 31, 2005 filed with the Securities and Exchange Commission on March 3, 2006.

Telik, the Telik
logo, TRAP, TELCYTA and TELINTRA are trademarks of Telik, Inc. All other brand names or trademarks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

Overview

Telik is engaged in the discovery,
development and commercialization of small molecule drugs. We have incurred net losses since inception and expect to incur substantial and increasing losses for the next several years as we expand our research and development activities and move our
product candidates into later stages of development. As of March 31, 2006, we had an accumulated deficit of $333.4 million.

Our
expenses have consisted primarily of those incurred for research and development and general and administrative costs associated with our operations. The process of carrying out the development of our product candidates to later stages of
development and our research programs may require significant additional research and development expenditures, including for preclinical testing and clinical trials, as well as for manufacturing development efforts and obtaining regulatory
approval. We outsource our clinical trials and our manufacturing development activities to third parties to maximize efficiency and minimize our internal overhead. To date, we have funded our operations primarily through the sale of equity
securities, including non-equity payments from collaborative partners.

We are subject to risks common to biopharmaceutical companies,
including risks inherent in our research, development and commercialization efforts, preclinical testing, clinical trials, uncertainty of regulatory and marketing approvals, enforcement of patent and proprietary rights, the need for future capital,
potential competition, use of hazardous materials and retention of key employees. In order for a product to be commercialized, it will be necessary for us to conduct preclinical tests and clinical trials, demonstrate efficacy



12



---

##### Table of Contents

and safety of our product candidates to the satisfaction of regulatory authorities, obtain marketing approval, enter into manufacturing, distribution and
marketing arrangements, obtain market acceptance and, in many cases, obtain adequate reimbursement from government and private insurers. We cannot provide assurance that we will generate revenues or achieve and sustain profitability in the future.

We expect that our quarterly and annual results of operations will fluctuate for the foreseeable future due to several factors, including
the timing and extent of our research and development efforts and the outcome of our clinical trial activities. The successful development of our products is uncertain. As such, an accurate prediction of future operating results is difficult or
impossible.

Clinical Status

TELCYTA,
our lead product candidate, is a small molecule tumor-activated cancer product candidate that we are evaluating initially to treat cancers that are resistant to standard chemotherapy drugs. We have three on-going Phase 3 registration trials with
TELCYTA. The first Phase 3 clinical trial (ASSIST-1) is for the treatment of advanced ovarian cancer. The second Phase 3 clinical trial (ASSIST-2) is for the treatment of advanced non-small cell lung cancer. The third Phase 3 clinical trial
(ASSIST-3) evaluates TELCYTA in combination with carboplatin for the treatment of second-line platinum resistant or refractory ovarian cancer. We plan to initiate a fourth Phase 3 clinical trial (ASSIST-5) in the second quarter of 2006 that
evaluates TELCYTA in combination with liposomal doxorubicin (Doxil/Caelyx) versus liposomal doxorubicin (Doxil/Caelyx) as second line therapy in platinum refractory or resistant ovarian cancer.

In addition, we have also conducted two Phase 2 clinical trials of TELCYTA for the treatment of Stage IIIb or IV non-small cell lung cancer for patients
who have not previously received chemotherapy. One clinical trial is in combination with cisplatin, and the other clinical trial is in combination with carboplatin and paclitaxel. Platinum and taxane-based drug combinations are the current standard
for the front-line chemotherapy of lung and ovarian cancer.

TELINTRA, our second product candidate, is a small molecule bone marrow
stimulant we are developing for the treatment of blood disorders associated with low blood cell levels, such as neutropenia or anemia. Our Phase 2 clinical trial in patients with MDS, a pre-leukemic condition, is completed and has not identified a
dose limiting toxicity. MDS is a disease characterized by defects in the blood-producing cells of the bone marrow, in which low blood cell levels occur. We announced positive clinical results at the American Society of Hematology annual meeting in
December 2005. In this study, clinically significant improvement was observed across all major MDS subtypes and in all blood cell lineages. TELINTRA was well-tolerated in this predominantly elderly patient population. We initiated a new Phase 2
study in MDS using a tablet formulation in February 2006.

We discovered all of our product candidates using our proprietary technology,
Target-Related Affinity Profiling, or TRAP, which enables the rapid and efficient discovery of small molecule product candidates. We expect to enter into collaborative arrangements with third parties for clinical trials, development, manufacturing,
regulatory approvals or commercialization of some of our products, particularly outside North America, or in disease areas requiring larger and longer clinical trials than cancer.

Critical Accounting Policies and Significant Judgments and Estimates

Our managements
discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial
statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and
expenses during the reporting periods. On an on-going basis, we evaluate our estimates and judgments related to clinical development costs. We base our estimates on historical experience and on various other factors that we believe are reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates under
different assumptions or conditions.



13



---

##### Table of Contents

We believe the following accounting policies are critical to the process of making significant judgments
and estimates in the preparation of our financial statements.

Share-based compensation expense

We grant stock options to our employees, outside directors and consultants and provide employees the right to purchase our stock pursuant to stockholder
approved stock option and employee stock purchase plans. The benefits provided under these plans are share-based payments subject to the provisions of revised Statement of Financial Accounting Standards No. 123, Share-Based Payment
(SFAS 123 (R)). Effective January 1, 2006, we adopted SFAS 123(R) and use the fair value method to account for share-based payments following the modified prospective method of adoption which provides for certain changes to the
method for valuing share-based compensation. The valuation provisions of SFAS 123(R) apply to new awards and to awards that are outstanding on the effective date and subsequently modified or cancelled. Under the modified prospective method of
adoption, prior periods are not revised for comparative purposes. Total compensation cost for our share-based payments recognized in the first quarter of 2006 was $3.6 million. There was no stock-based compensation expense related to employee stock
options and employee stock purchases recognized in the first quarter of 2005. As of March 31, 2006, $22.0 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average
period of 2.52 years.

The fair value of each option award is estimated on the date of grant using a Black-Scholes-Merton option
pricing model (Black-Scholes model) that uses assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, our expected volatility, expected term, risk-free interest rate and
expected dividends. Expected volatilities are based on historical volatility of our common stock and other factors. The expected term of options granted is based on the simplified method in accordance with the SECs Staff Accounting Bulletin
No. 107 (SAB 107) as our historical share option exercise experience does not provide a reasonable basis for estimation. The risk-free interest rates are based on the U.S. Treasury yield in effect at the time of the grant. Since we
do not expect to pay dividends on our common stock in the foreseeable future, we estimated the dividend yield to be 0%. SFAS 123(R) requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual
forfeitures differ from those estimates. We estimate pre-vesting forfeitures based on our historical experience. The weighted-average estimated value of employee stock options granted during the three months March 31, 2006 was $12.50 per share
using the Black-Scholes model with the following weighted-average assumptions:



|                         |                    |                                   |   |                     |               
|------------------------ | ------------------ | --------------------------------- | - | ------------------- | --------------
|                         |                    | Three Months Ended March 31, 2006
|                         | Stock Option Plans |                                   |   | Stock Purchase Plan
|Expected volatility      |                    | 63.1                              | % |                     | 35.6 %  38.8%
|Risk-free interest rate  |                    | 4.56                              | % |                     | 4.58%  4.74% 
|Expected life (in years) |                    | 6.08                              |   |                     | 0.5  1.5     
|Expected dividend yield  |                    |                                  |   |                     |              

If factors change and we develop different assumptions in the application of SFAS 123(R) in future
periods, the compensation expense that we record under SFAS 123(R) may differ significantly from what we have recorded in the current period. There is a high degree of subjectivity involved when using option pricing models to estimate share-based
compensation under SFAS 123(R). Because changes in the subjective input assumptions can materially affect our estimates of fair values of our share-based compensation, in our opinion, existing valuation models, including the Black-Scholes and
lattice binomial models, may not provide reliable measures of the fair values of our share-based compensation. Consequently, there is a risk that our estimates of the fair values of our share-based compensation awards on the grant dates may bear
little resemblance to the actual values realized upon the exercise, early termination or forfeiture of those share-based payments in the future. Certain share-based payments, such as employee stock options, may expire worthless or otherwise result
in zero intrinsic value as compared to the fair values originally estimated on the grant date and reported



14



---

##### Table of Contents

in our financial statements. Alternatively, values may be realized from these instruments that are significantly in excess of the fair values originally
estimated on the grant date and reported in our financial statements. There is currently no market-based mechanism or other practical application to verify the reliability and accuracy of the estimates stemming from these valuation models, nor is
there a means to compare and adjust the estimates to actual values. Although the fair value of employee share-based awards is determined in accordance with SFAS 123(R) and SAB 107 using an option- pricing model, that value may not be indicative of
the fair value observed in a willing buyer/willing seller market transaction.

The guidance in SFAS 123 (R) and SAB 107 is relatively
new, and best practices are not well established. The application of these principles may be subject to further interpretation and refinement over time. There are significant differences among valuation models. Theoretical valuation models and
market-based methods are evolving and may result in lower or higher fair value estimates for share-base compensation. This may result in a lack of comparability with other companies that use different models, methods and assumptions.

Research and development expenses

Our research and
development expenses include salaries and benefits costs, fees for contractors, consultants and third-party contract research organizations and an allocation of facility and administrative costs. Research and development expenses consist of costs
incurred for drug and product development, manufacturing, clinical activities, discovery research, screening and identification of product candidates, and preclinical studies. All such costs are charged to research and development expenses as
incurred.

Clinical development costs are a significant component of research and development expenses. We have a history of contracting
with third parties that perform various clinical trial activities on our behalf in the on-going development of our product candidates. The financial terms of these contracts are subject to negotiation and may vary from contract to contract and may
result in uneven payment flows. We accrue and expense costs for clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements
established with contract research organizations and clinical trial sites. We determine our estimates through discussion with internal clinical personnel and outside service providers as to progress or stage of completion of trials or services and
the agreed upon fee to be paid for such services. These estimates may or may not match the actual services performed by the organizations as determined by patient enrollment levels and related activities. We monitor patient enrollment levels and
related activities to the extent possible; however, if we underestimate activity levels associated with various studies at a given point in time, we could record significant research and development expenses in future periods.

Use of estimates

In preparing our financial
statements to conform with U.S. generally accepted accounting principles, we make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. Actual results may differ from these estimates.

Results of operations

Revenues



|         |  |                                   |   |      |   |          |  |      |   
|-------- |  | --------------------------------- | - | ---- | - | -------- |  | ---- | --
|         |  | Three Months EndedMarch 31,       |   |      |  
|         |  | 2006                              |   | 2005 |   | % Change | 
|         |  | (in thousands, except percentage) |  
|Revenues |  | $                                 |  |      | $ | 19       |  | (100 | )%



15



---

##### Table of Contents

Revenue in the three months ended March 31, 2005 resulted from our collaborative agreement and the
completion of our compound identification revenue amortization with Hoffman La-Roche, Inc. There was no collaborative research agreements in the three months ended March 31, 2006.

We expect near-term revenues to fluctuate primarily depending upon the extent to which we enter into new collaborative research agreements and the
amounts of payments relating to such agreements.

Research and development expenses

Research and development expenses for the three months ended March 31, 2006 and 2005 were $17.7 million and $19.1 million. Our research and
development activities consist primarily of drug development, clinical supply manufacturing, clinical activities, discovery research, screening and identification of product candidates and preclinical studies. We group these activities into two
major categories: research and preclinical and clinical development.

The approximate costs associated with
research and preclinical and clinical development activities were as follows:



|                               |  |                                    |        |      |   |          |  |     |   
|------------------------------ |  | ---------------------------------- | ------ | ---- | - | -------- |  | --- | --
|                               |  | Three Months Ended March 31,       |       
|                               |  | 2006                               |        | 2005 |   | % Change | 
|                               |  | (In thousands, except percentages) |       
|Research and preclinical       |  | $                                  | 5,533  |      | $ | 4,724    |  | 17  | % 
|Clinical development           |  |                                    | 12,125 |      |   | 14,421   |  | (16 | )%
|                               |  |                                    |        |      |   |          |  |     |   
|Total research and development |  | $                                  | 17,658 |      | $ | 19,145   |  | (8  | )%
|                               |  |                                    |        |      |   |          |  |     |   

The decrease of 8%, or $1.5 million, in research and development expenses for the three months
ended March 31, 2006 compared to the same period in 2005 was principally due to the following:



| |  |  | decreased costs associated with our Phase 3 clinical trials in ovarian cancer and non-small cell lung cancer of approximately $5.6 million as a result of the completion of patient
enrollment in our ASSIST-1 and ASSIST-2 clinical trials partially offset by increased costs of approximately $0.9 million due to our on-going ASSIST-3 clinical trial and initial start-up costs related to our ASSIST-5 clinical trial;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | approximately $1.1 million associated with headcount growth and increased expenses to support clinical activities; and
| | - |  | ----------------------------------------------------------------------------------------------------------------------



| |  |  | share-based compensation expense of approximately $2.3 million.
| | - |  | ---------------------------------------------------------------

We expect research and development expenditures to increase in the future as a result of increased manufacturing and clinical development costs primarily relating to development of our TELCYTA and TELINTRA product candidates. The timing and
the amount of these expenditures will depend upon the outcome of our on-going clinical trials, the costs associated with the Phase 3 clinical trials of TELCYTA, including related expansion of our research and development organization, regulatory
requirements, advancement of our preclinical programs and product manufacturing costs.

The following table summarizes our principal
product candidate development initiatives, including the related stages of development for each product in development and the research and development expenses recognized in connection with each product candidate. The information in the column
labeled Estimated or Actual Completion of Enrollment is our current estimate of the timing of completion of enrollment. The actual timing of completion of enrollment could differ materially from the estimates provided in the table. For a
discussion of the risks and uncertainties associated with the timing of completing a product development phase, see the risk factors All of our product candidates are in research and development. If clinical trials of TELCYTA or TELINTRA are
delayed or unsuccessful or if we are unable to complete the preclinical development of our other preclinical product candidates, our business may suffer, If we do not obtain



16



---

##### Table of Contents

regulatory approval to market products in the United States and foreign countries, we or our collaborators will not be permitted to commercialize our product
candidates, As our product programs advance, we will need to hire additional scientific and management personnel. Our research and development efforts will be seriously jeopardized if we are unable to attract and retain key
personnel, and If we are unable to enter into or maintain existing contracts with third parties to manufacture our product candidates or any products that we may develop in sufficient quantities and at an acceptable cost, clinical
development of product candidates could be delayed and we may be unable to meet demand for any products that we may develop and lose potential revenue as described in Part II, Item 1A Risk Factors below.



|                                       |  |                                |  |                     |  |                                          |        |                                                   |        |        |   |       
|-------------------------------------- |  | ------------------------------ |  | ------------------- |  | ---------------------------------------- | ------ | ------------------------------------------------- | ------ | ------ | - | ------
|Product                                |  | Description                    |  | Phase ofDevelopment |  | Estimatedor ActualCompletionofEnrollment |        | Related R&D Expenses Three Months Ended March 31,
|                                       |  |                                |  | 2006                |  | 2005                                    
|                                       |  |                                |  |                     |  |                                          |        | (in thousands)                                   
|TELCYTA                                |  |                                |  |                     |  |                                          |        | $                                                 | 11,936 |        | $ | 13,806
|                                       |  | Ovarian, ASSIST-1              |  | Phase 3             |  | 2004                                     |        |                                                   |        |        |   |       
|                                       |  | Non-small cell lung, ASSIST-2  |  | Phase 3             |  | 2005                                     |        |                                                   |        |        |   |       
|                                       |  | Ovarian, ASSIST-3              |  | Phase 3             |  | 2006                                     |        |                                                   |        |        |   |       
|                                       |  | Ovarian, ASSIST-5              |  | Phase 3             |  | 2007                                     |        |                                                   |        |        |   |       
|                                       |  | Combination (with other drugs) |  | Phase 2             |  | 2006                                     |        |                                                   |        |        |   |       
|                                       |  |                                |  |                     | 
|TELINTRA                               |  | MDS                            |  | Phase 1-2           |  | 2005                                     |        |                                                   | 994    |        |   | 1,301 
|                                       |  | MDS tablet formulation         |  | Phase 2             |  | 2007                                     |        |                                                   |        |        |   |       
|Other (1)                              |  |                                |  |                     |  |                                          |        |                                                   | 4,728  |        |   | 4,038 
|                                       |  |                                |  |                     |  |                                          |        |                                                   |        |        |   |       
|Total research and development expense |  |                                |  |                     |  | $                                        | 17,658 |                                                   | $      | 19,145
|                                       |  |                                |  |                     |  |                                          |        |                                                   |        |        |   |       

---

|(1) | Other constitutes research and development activities performed by our Chemistry, Biology, preclinical and Quality Assurance departments as these costs cannot be
allocated to any individual project.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The largest component of our total operating expenses is our on-going investments in
our research and development activities and, in particular, the clinical development of our product candidate pipeline. The process of conducting the clinical research necessary to obtain FDA approval is costly and time consuming. Current FDA
requirements for a new human drug to be marketed in the United States include:



| |  |  | the successful conclusion of preclinical laboratory and animal tests, if appropriate, to gain preliminary information on the drug product candidates safety;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | filing with the FDA of an IND, to conduct initial human clinical trials for drug candidates;
| | - |  | --------------------------------------------------------------------------------------------



| |  |  | the successful completion of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug product candidate; and
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | filing by us and acceptance and approval by the FDA of a New Drug Application, or NDA, for a drug product candidate to allow commercial distribution of the drug.
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------

In view of the factors mentioned above, we consider the active management and development of our clinical pipeline to be
crucial to our long-term success. The actual probability of success for each candidate and clinical program may be impacted by a variety of factors, including, among others, the quality of the candidate, the validity of the target and disease
indication, early clinical data, investment in the program, competition, manufacturing capability and commercial viability. Due to these and other factors, it is difficult to give accurate guidance on the anticipated proportion of our research and
development investments or the future cash inflows from these programs.



17



---

##### Table of Contents

General and administrative expenses



|                           |  |                                   |       |          |   |       |  |    |  
|-------------------------- |  | --------------------------------- | ----- | -------- | - | ----- |  | -- | -
|                           |  | Three Months EndedMarch 31,       |       | % Change |  
|                           |  | 2006                              |       | 2005     |  
|                           |  | (In thousands, except percentage) |      
|General and administrative |  | $                                 | 4,509 |          | $ | 2,633 |  | 71 | %

The increase of 71%, or $1.9 million, in general and administrative expenses for the three months
ended March 31, 2006 compared to the same period in 2005 was primarily due to share-based compensation expense of $1.3 million, increased expenses necessary to manage the growth of our operations of $296,000 and approximately $231,000 in
marketing expenses due to increased marketing program activities for TELCYTA.

We expect future general and administrative expenses to
increase in support of expanded business activities including costs associated with our marketing efforts to support our commercialization strategy for TELCYTA.

Interest income and interest expense



|                 |  |                                    |       |          |   |       |  |     |   
|---------------- |  | ---------------------------------- | ----- | -------- | - | ----- |  | --- | --
|                 |  | Three Months EndedMarch 31,        |       | % Change |  
|                 |  | 2006                               |       | 2005     |  
|                 |  | (In thousands, except percentages) |      
|Interest income  |  | $                                  | 2,107 |          | $ | 1,377 |  | 53  | % 
|Interest expense |  | $                                  | 16    |          | $ | 42    |  | (62 | )%

Interest income of $2.1 million and $1.4 million for the three months ended March 31, 2006
and 2005 resulted primarily from earnings on investments. The increase in net interest income of $730,000 in the first three months of 2006 compared to the same period in 2005 was due to higher average interest rates in 2006 and higher principal
balances of our investments as a result of $142.2 million in net proceeds obtained from our follow-on offering in February 2005.

Interest
expense was $16,000 and $42,000 for the three months ended March 31, 2006 and 2005. The decrease in interest expense in the first three months of 2006 compared to the same period in 2005 was a result of no new borrowings since 2004 and payments
on our lease and loan obligations. We expect interest expenditures to continue to decrease in the future as we pay down our lease and loan obligations.

Liquidity and capital resources



|                                                              |  |                              |        |   |      |   |        |  
|------------------------------------------------------------- |  | ---------------------------- | ------ | - | ---- | - | ------ | -
|                                                              |  | 2006                         |        |   | 2005 |  
|                                                              |  | (In millions, except ratios) |       
|March 31:                                                     |  |                              |        |   |      |   |        |  
|Cash, cash equivalents, investments and restricted cash       |  | $                            | 187.1  |   |      | $ | 260.0  |  
|Working capital                                               |  | $                            | 173.0  |   |      | $ | 243.1  |  
|Current ratio                                                 |  |                              | 13.1:1 |   |      |   | 14.9:1 |  
|                                                              |  |                             
|Three months ended March 31:                                  |  |                              |        |   |      |   |        |  
|Cash (used in) / provided by:                                 |  |                              |        |   |      |   |        |  
|Operating activities                                          |  | $                            | (19.9  | ) |      | $ | (20.8  | )
|Investing activities                                          |  | $                            | (11.2  | ) |      | $ | (34.5  | )
|Financing activities                                          |  | $                            | 1.6    |   |      | $ | 142.7  |  
|Capital expenditures (included in investing activities above) |  | $                            | (0.1   | ) |      | $ | (0.3   | )

Sources and Uses of Cash. Due to the significant research and development expenditures and
the lack of any approved products to generate revenue, we have not been profitable and have generated operating losses since we incorporated in 1988. As such, we have funded our research and development operations through



18



---

##### Table of Contents

sale of equity securities, non-equity payments from corporate partners, interest earned on investments and equipment lease and loan financings. At
March 31, 2006, we had available cash, cash equivalents, investments and restricted investments of $187.1 million. Our cash and investment balances are held in a variety of interest-bearing instruments including obligations of U.S. government
agencies, high-grade corporate and municipal bonds, commercial paper, auction rate securities and money market accounts. Cash in excess of immediate requirements is invested with regard to liquidity and capital preservation. Wherever possible, we
seek to minimize the potential effects of concentration and degrees of risk.

Cash Flows from Operating Activities. Cash used in
operations for the three months ended March 31, 2006 was $19.9 million compared with $20.8 million for the same period in 2005. Net loss of $20.2 million in 2006 included non-cash charges of $3.6 million for share-based compensation and
$442,000 for depreciation and amortization. Cash used in operations was further impacted by decreases of $2.2 million in accrued compensation expense primarily due to bonus payouts and $2.6 million in accrued clinical trial payments related
primarily to our Phase 3 clinical trials. Cash outflows in 2006 were offset by an increase of $692,000 in accounts payable. Cash used in operations for the same period in 2005 consisted of net loss of $20.4 million and included non-cash charges
of $363,000 for depreciation and amortization. Cash used in operations for the same period was further impacted by decreases of $1.8 million in accrued compensation expense due to bonus payouts and $401,000 in deferred rent expense. Cash outflows
were offset by increases of $806,000 in accounts payable and $685,000 in accrued clinical trial expenses related primarily to our Phase 3 clinical trials.

Cash Flows from Investing Activities. Cash used in investing activities for the three months ended March 31, 2006 was $11.2 million compared with cash used in investing activities of $34.5 million for the
same period in 2005. Cash used for the three months ended March 31, 2006 was primarily for $19.0 million in purchases of short-term available-for-sale investments offset by $8.0 million in sales and maturities of investments. Capital
expenditures for the same period were $140,000 primarily for laboratory, office and computer equipment purchases. Cash used for the three months ended March 31, 2005 was primarily for $63.8 million in purchases of short-term available-for-sale
investments offset by $29.6 million in sales and maturities of investments. Capital expenditures for the same period were $342,000 primarily for laboratory and computer equipment purchases.

Cash Flows from Financing Activities. Cash provided by financing activities for the three months ended March 31, 2006 was approximately $1.6
million compared with $142.7 million for the same period in 2005. Financing activities for the three months ended March 31, 2006 included $1.9 million in proceeds from stock option exercises and our employee stock purchase plan, offset in part
by $321,000 in payments under capital leases and equipment loans. Financing activities for the three months ended March 31, 2005 included approximately $142.2 million in net proceeds from our follow-on public offering of common stock completed
in February 2005.

Working Capital. Working capital decreased to $173.0 million at March 31, 2006 from $243.1 million at
March 31, 2005. The decrease in working capital was primarily due to our use of cash in operations due to the expansion of our TELCYTA development program and costs associated with headcount growth.

In February 2005, we completed a follow-on public offering of 8,050,000 shares of common stock, including shares issued in connection with the
underwriters exercise in full of their over-allotment option, at a public offering price of $18.75 per share, raising net proceeds of approximately $142.2 million after deducting underwriters discounts and commissions, and related
offering expenses.

We believe our existing cash resources and investment securities will be sufficient to support our current operating
plan until the end of 2007. We expect the clinical development expenses as a result of our Phase 3 clinical trials to consume a large portion of our existing cash resources. Changes in our research and development plans or other changes affecting
our operating expenses may affect actual future consumption of existing cash resources as well. In any event, we will require substantial additional financing to fund our operations in the future. We may seek to raise any necessary additional funds
through equity or debt financings, collaborative arrangements with corporate partners or other sources. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience dilution. Debt financing may subject
us to restrictive covenants that may adversely affect our operations. To the extent that we raise



19



---

##### Table of Contents

additional capital through licensing arrangements or arrangements with collaborative partners, we may be required to relinquish, on terms that are not
favorable to us, rights to some of our technologies or product candidates that we would otherwise seek to develop or commercialize ourselves. Our future capital uses and requirements depend on numerous factors, including the following:



| |  |  | the progress and success of preclinical studies and clinical trials of our product candidates;
| | - |  | ----------------------------------------------------------------------------------------------



| |  |  | the progress and number of research programs in development;
| | - |  | ------------------------------------------------------------



| |  |  | the costs associated with conducting Phase 3 clinical trials;
| | - |  | -------------------------------------------------------------



| |  |  | the costs and timing of obtaining regulatory approvals;
| | - |  | -------------------------------------------------------



| |  |  | our ability to establish, and the scope of, any new collaborations;
| | - |  | -------------------------------------------------------------------



| |  |  | our ability to meet the milestones identified in our collaborative agreements that trigger payments;
| | - |  | ----------------------------------------------------------------------------------------------------



| |  |  | the costs and timing of obtaining, enforcing and defending our patent and intellectual property rights;
| | - |  | -------------------------------------------------------------------------------------------------------



| |  |  | competing technological and market developments; and
| | - |  | ----------------------------------------------------



| |  |  | the timing and scope of commercialization expenses for our product candidates as they approach regulatory approval.
| | - |  | -------------------------------------------------------------------------------------------------------------------

We currently have no commitments for any additional financings. If we need to raise additional money to fund our operations, funding may not be available
to us on acceptable terms, or at all. If we are unable to raise additional funds when needed, we may not be able to continue development of our product candidates, or we could be required to delay, scale back or eliminate some or all of our research
and development programs.

Our future contractual obligations at March 31, 2006 were as follows:



|                                   |                |       |        |      |   |           |  |           |       |            |   |       |  |   |       
|---------------------------------- | -------------- | ----- | ------ | ---- | - | --------- |  | --------- | ----- | ---------- | - | ----- |  | - | ------
|                                   |                | Total |        | 2006 |   | 2007-2008 |  | 2009-2010 |       | After 2010
|                                   | (In thousands)
|Capital lease obligations          |                | $     | 189    |      | $ | 189       |  | $         |      |            | $ |      |  | $ |      
|Equipment loans                    |                |       | 631    |      |   | 429       |  |           | 202   |            |   |      |  |   |      
|Operating leases                   |                |       | 29,505 |      |   | 2,498     |  |           | 6,913 |            |   | 7,284 |  |   | 12,810
|                                   |                |       |        |      |   |           |  |           |       |            |   |       |  |   |       
|Total contractual cash obligations |                | $     | 30,325 |      | $ | 3,116     |  | $         | 7,115 |            | $ | 7,284 |  | $ | 12,810
|                                   |                |       |        |      |   |           |  |           |       |            |   |       |  |   |       

We have a contractual obligation under the terms of our manufacturing supply agreement with
Organichem Corporation, wherein we are obligated to purchase a significant percentage of our United States requirements for the active ingredient in TELCYTA for a number of years. We have agreed on a pricing schedule for such supply, which will be
subject to future renegotiation after a defined time period.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The following discussion about our
market risk exposure involves forward-looking statements. We are exposed to market risk related mainly to changes in interest rates and we believe our exposure to market risk is immaterial. We do not use or hold derivative financial instruments.

Our investment policy is to manage our marketable securities portfolio to preserve principal and liquidity while maximizing the return on
the investment portfolio. To minimize the exposure due to adverse shifts in interest rates we maintain investments of shorter maturities. Our marketable securities portfolio is primarily invested in corporate debt securities and commercial papers
with an average maturity of under one year and a minimum investment grade rating of A or A-1 or better to minimize credit risk. Although changes in interest rates may affect the fair value of the marketable securities portfolio and cause unrealized
gains or losses, such gains or losses would not be realized unless the investments were sold prior to maturity. Through our money managers, we maintain risk management control systems to monitor interest rate risk. The risk management control
systems use analytical techniques, including sensitivity analysis. We have operated primarily in the United States and all funding activities with our collaborators to date have been made in U.S. dollars. Accordingly, we do not have any exposure to
foreign currency rate fluctuations.



20



---

##### Table of Contents

The table below presents the principal amounts and weighted-average interest rates by year of stated
maturity for our investment portfolio:



|                              |                                    |      |         |   |      |   |        |                |  |   |        |   |  |                            |         |   |  |   |        
|----------------------------- | ---------------------------------- | ---- | ------- | - | ---- | - | ------ | -------------- |  | - | ------ | - |  | -------------------------- | ------- | - |  | - | -------
|                              |                                    | 2006 |         |   | 2007 |   |        | 2008 andBeyond |  |   | Total  |   |  | Fair Value atMarch 31,2006
|                              | (In thousands, except percentages)
|Available-for-sale securities |                                    | $    | 124,131 |   |      | $ | 20,307 |                |  | $ | 32,998 |   |  | $                          | 177,436 |   |  | $ | 177,130
|Average interest rate         |                                    |      | 4.43    | % |      |   | 4.41   | %              |  |   | 4.97   | % |  |                            | 4.53    | % |  |   |        

Item 4. Controls and Procedures.

Evaluation of disclosure controls and procedures. Based on our
managements evaluation (with the participation of our chief executive officer and chief financial officer), our chief executive officer and chief financial officer have concluded that, subject to limitations described below, our disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), were effective as of March 31, 2006 to ensure that information required to be disclosed by us in reports that we file
or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commissions rules and forms.

Changes in internal control. There were no changes in our internal control over financial reporting during the quarter ended March 31, 2006
that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the effectiveness of controls. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent
limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide
reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our chief executive officer and chief financial officer have concluded, based on their evaluation as of the end of the period
covered by this report, that our disclosure controls and procedures were sufficiently effective to provide reasonable assurance that the objectives of our disclosure control system were met.



21



---

##### Table of Contents

PART II. OTHER INFORMATION

Item 1A. Risk Factors.

Included below is a description of risk factors related to our business to
enable readers to assess, and be appropriately apprised of, many of the risks and uncertainties applicable to the forward-looking statements made in this Quarterly Report on Form 10-Q. The risks and uncertainties set forth below are not all of the
risks and uncertainties facing our business, but we do believe that they reflect the more important ones. You should carefully consider these risk factors as each of these risks could adversely affect our business, operating results and financial
condition. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements.

The
risk factors described in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2005, as filed with the SEC on March 3, 2006, are set forth below. These risk factors have not substantively changed, except
for those identified by asterisk and restated below.

We have a history of net losses, which we expect to continue for the next several years. We
will never be profitable unless we develop, and obtain regulatory approval and market acceptance of, our product candidates.*

Due to
the significant research and development expenditures required to develop our TRAP technology and identify new product candidates, and the lack of any products to generate revenue, we have not been profitable and have incurred operating losses since
we were incorporated in 1988. As of March 31, 2006, we had an accumulated deficit of $333.4 million. We expect to incur losses for the next several years as we continue our research and development activities and incur significant clinical
testing costs. We do not anticipate that we will generate product revenue for several years. Our losses, among other things, have caused and will cause our stockholders equity and working capital to decrease. To date, we have derived
substantially all of our revenues, which have not been significant, from project initiation fees and research reimbursement paid pursuant to existing collaborative agreements with third parties and achievement of milestones under current
collaborations. We expect that this trend will continue until we develop, and obtain regulatory approval and market acceptance of, our product candidates, if at all. We may never generate product revenue sufficient to become profitable.

All of our product candidates are in research and development. If clinical trials of TELCYTA or TELINTRA are delayed or unsuccessful or if we are unable to
complete the preclinical development of our other preclinical product candidates, our business may suffer.*

Preclinical testing and
clinical trials are long, expensive and uncertain processes. It may take us or our collaborators several years to complete this testing, and failure can occur at any stage of the process. Success in preclinical testing and early clinical trials does
not ensure that later clinical trials will be successful, and interim results of clinical trials do not necessarily predict final results. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered
significant setbacks in advanced clinical trials, even after promising results in earlier clinical trials.

TELCYTA has to date been
evaluated in Phase 1 and Phase 2 clinical trials. We have three ongoing Phase 3 registration trials of TELCYTA. These Phase 3 clinical trials test TELCYTA against a control arm consisting of currently established standard drug treatments for ovarian
and lung cancers. Changes in standards of care during our Phase 3 clinical trials may cause us to, or the FDA may require us to, perform additional clinical testing of TELCYTA against a different control arm prior to filing an NDA, for marketing
approval. Our short-term success depends to a significant extent on the outcome of these trials. If the results of one or more of these trials do not demonstrate sufficient efficacy to support our NDA, then our business may suffer.

We completed a Phase 2 clinical trial of TELINTRA in MDS, a form of pre-leukemia, to evaluate safety, pharmacokinetics, pharmacodynamics and efficacy. We
received permission to proceed, under an IND application filed with the FDA, with the clinical study of a tablet formulation of TELINTRA. Our success depends, in part, on our ability to complete clinical development of TELINTRA or other preclinical
product candidates and take them through early clinical trials.



22



---

##### Table of Contents

Any clinical trial may fail to produce results satisfactory to the FDA. Preclinical and clinical data can
be interpreted in different ways, which could delay, limit or prevent regulatory approval. Negative or inconclusive results or adverse medical events during a clinical trial could cause a clinical trial to be repeated or a program to be terminated.
We typically rely on third-party clinical investigators to conduct our clinical trials and, as a result, we may face additional delays outside our control. We have engaged contract research organizations, or CROs, to facilitate the administration of
our Phase 3 clinical trials of TELCYTA. Dependence on a CRO subjects us to a number of risks. We may not be able to control the amount and timing of resources the CRO may devote to our clinical trials. Should the CRO fail to administer our Phase 3
clinical trials properly, regulatory approval, development and commercialization of TELCYTA will be delayed.

We do not know whether we
will begin planned clinical trials on time or whether we will complete any of our on-going clinical trials on schedule, if at all. We do not know whether any clinical trials will result in marketable products. Typically, there is a high rate of
failure for product candidates in preclinical and clinical trials. We do not anticipate that any of our product candidates will reach the market for several years.

Significant delays in clinical testing could materially impact our clinical trials. We do not know whether planned clinical trials will begin on time, will need to be revamped or will be completed on schedule, if at
all. In addition to the reasons stated above, clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a study, delays in reaching agreement on acceptable clinical study agreement terms
with prospective clinical sites, delays in obtaining institutional review board approval to conduct a study at a prospective clinical site and delays in recruiting subjects to participate in a study.

Delays can also materially impact our product development costs. If we experience delays in testing or approvals, our product development costs will
increase. For example, we may need to make additional payments to third-party investigators and organizations to retain their services or we may need to pay recruitment incentives. If the delays are significant, our financial results and the
commercial prospects for our product candidates will be harmed, and our ability to become profitable will be delayed.

We believe that our ability to
compete depends, in part, on our ability to use our proprietary

TRAP technology to discover new pharmaceutical products.

TRAP, our proprietary drug discovery technology, is a relatively new drug discovery method that uses a protein panel of approximately 20 proteins selected
for their distinct patterns of interacting with small molecules. This panel may lack essential types of interactions that we have not yet identified, which may result in our inability to identify active compounds that we could potentially develop
into commercially viable drugs.

If we are unable to raise adequate funds in the future, we will not be able to continue to fund our operations,
research programs, preclinical testing and clinical trials to develop our product candidates.*

The process of carrying out the
development of our own unpartnered product candidates to later stages of development and developing other research programs to the stage that they may be partnered will require significant additional expenditures, including the expenses associated
with preclinical testing, clinical trials and obtaining regulatory approval. We believe that our existing cash and investment securities will be sufficient to support our current operating plan until the end of 2007. Changes in our research and
development plans or other changes affecting our operating expenses may affect actual future consumption of existing cash resources as well. In any event, we will require substantial additional financing to fund our operations in the future. We do
not know whether additional financing will be available when needed or that, if available, we will obtain financing on terms favorable to our stockholders. As of March 31, 2006, our accumulated deficit was $333.4 million, and we expect capital
outlays and operating expenditures to increase over the next several years as we expand our clinical, research and development activities. The extent of any actual increase in operating or capital spending will depend in part on the clinical success
of our product candidates. If we fail to raise adequate funds on terms acceptable to us, if at all, we will not be able to continue to fund our operations, research programs, preclinical testing and clinical trials.



23



---

##### Table of Contents

Raising additional capital by issuing securities or through collaboration and licensing arrangements may cause
dilution to existing stockholders or require us to relinquish rights to our technologies or product candidates.

We may seek to raise
any necessary additional funds through equity or debt financings, collaborative arrangements with corporate partners or other sources. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience
dilution. To the extent that we raise additional capital through licensing arrangements or arrangements with collaborative partners, we may be required to relinquish, on terms that are not favorable to us, rights to some of our technologies or
product candidates that we would otherwise seek to develop or commercialize ourselves.

If our competitors develop and market products that are more
effective than our product candidates or any products that we may develop, or obtain marketing approval before we do, our commercial opportunity will be reduced or eliminated.

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Some of the drugs
that we are attempting to develop will have to compete with existing therapies. In addition, a large number of companies are pursuing the development of pharmaceuticals that target the same diseases and conditions that we are targeting. We face
competition from pharmaceutical and biotechnology companies in the United States and abroad. Our competitors may develop new screening technologies and may utilize discovery techniques or partner with collaborators in order to develop products more
rapidly or successfully than we or our collaborators are able to do.

Many of our competitors, particularly large pharmaceutical companies,
have substantially greater financial, technical and human resources than we do. These organizations also compete with us to attract qualified personnel and parties for acquisitions, joint ventures, licensing arrangements or other collaborations. In
addition, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish exclusive collaborative
or licensing relationships with our competitors.

Our competitors may succeed in developing technologies and drugs that are more effective,
better tolerated or less costly than any which are being developed by us or which would render our technology and potential drugs obsolete and noncompetitive. In addition, our competitors may succeed in obtaining FDA or other regulatory approvals
for product candidates more rapidly than us or our collaborators. Any drugs resulting from our research and development efforts, or from our joint efforts with our existing or future collaborative partners, may not be able to compete successfully
with our competitors existing products or products under development or may not obtain regulatory approval in the United States or elsewhere.

If
we do not obtain regulatory approval to market products in the United States and foreign countries, we or our collaborators will not be permitted to commercialize our product candidates.*

Even if we are able to achieve success in our preclinical testing, we, or our collaborators, must provide the FDA and foreign regulatory authorities with
clinical data that demonstrate the safety and efficacy of our product candidates in humans before they can be approved for commercial sale. Failure to obtain regulatory approval will prevent commercialization of our product candidates.

The pharmaceutical industry is subject to stringent regulation by a wide range of regulatory authorities. We cannot predict whether regulatory
clearance will be obtained for any product candidate that we are developing or hope to develop. A pharmaceutical product cannot be marketed in the United States until it has completed rigorous preclinical testing and clinical trials and an extensive
regulatory clearance process implemented by the FDA. Satisfaction of regulatory requirements typically takes many years and depends on the type, complexity and novelty of the product and requires the expenditure of substantial resources. Of
particular significance are the requirements covering research and development, testing, manufacturing, quality control, labeling and promotion of drugs for human use.



24



---

##### Table of Contents

Before commencing clinical trials in humans, we, or our collaborators, must submit and receive approval
from the FDA of an IND application. We must comply with FDA Good Laboratory Practices regulations in our preclinical studies. Clinical trials are subject to oversight by institutional review boards of participating clinical sites and the
FDA and:



| |  |  | must be conducted in conformance with the FDA regulations;
| | - |  | ----------------------------------------------------------



| |  |  | must meet requirements for institutional review board approval;
| | - |  | ---------------------------------------------------------------



| |  |  | must meet requirements for informed consent;
| | - |  | --------------------------------------------



| |  |  | must meet requirements for Good Clinical Practices;
| | - |  | ---------------------------------------------------



| |  |  | may require large numbers of participants; and
| | - |  | ----------------------------------------------



| |  |  | may be suspended by us, our collaborators or the FDA at any time if it is believed that the subjects participating in these trials are being exposed to unacceptable health risks or
if the FDA finds deficiencies in the IND application or the conduct of these trials.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Before receiving FDA clearance to
market a product, we, or our collaborators must demonstrate that the product candidate is safe and effective in the patient population that will be treated. Negative or inconclusive results or adverse medical events during a clinical trial could
cause a clinical trial to be repeated, a program to be terminated and could delay approval. We typically rely on third-party clinical investigators to conduct our clinical trials and other third-party organizations to perform data collection and
analysis. As a result, we may face additional delaying factors outside our control. In addition, we may encounter delays or rejections based upon additional government regulation from future legislation or administrative action or changes in FDA
policy or interpretation during the period of product development, clinical trials and FDA regulatory review. Failure to comply with applicable FDA or other applicable regulatory requirements may result in criminal prosecution, civil penalties,
recall or seizure of products, total or partial suspension of production or injunction, as well as other regulatory action. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approval.

If regulatory clearance of a product is granted, this clearance will be limited to those disease states and conditions for which the
product is demonstrated through clinical trials to be safe and efficacious, which could limit our market opportunity. Furthermore, product approvals, once granted, may be withdrawn if problems occur after initial marketing. We cannot ensure that any
compound developed by us, alone or with others, will prove to be safe and efficacious in clinical trials and will meet all of the applicable regulatory requirements needed to receive marketing clearance. Regulatory clearance may also contain
requirements for costly post-marketing testing and surveillance to monitor the safety and efficacy of the product. If problems occur after initial marketing, such as the discovery of previously unknown problems with our product candidates, including
unanticipated adverse events or adverse events of unanticipated severity or frequency, or manufacturer or manufacturing issues, marketing approval can be withdrawn.

Outside the United States, the ability to market a product depends on receiving a marketing authorization from the appropriate regulatory authorities. Most foreign regulatory approval processes include all of the
risks associated with FDA clearance described above and some may include additional risks.

As our product programs advance, we will need to hire
additional scientific and management personnel. Our research and development efforts will be seriously jeopardized if we are unable to attract and retain key personnel.

Our success depends in part on the continued contributions of our principal management and scientific personnel and on our ability to develop and maintain
important relationships with leading academic institutions, scientists and companies in the face of intense competition for such personnel. As we plan for and commence additional advanced clinical trials, including Phase 2 and Phase 3, we will also
need to further expand our clinical development personnel. In addition, our research programs depend on our ability to attract and retain highly skilled chemists and other scientists. If we lose the services of Dr. Wick or any of our other key
personnel, our research and development efforts could be seriously and adversely affected. We have generally entered into consulting or other agreements with our scientific and clinical collaborators and advisors. We do not carry key person
insurance that covers Dr. Wick or any of our other key employees. There is currently a shortage of skilled executives and employees with technical expertise in the biotechnology



25



---

##### Table of Contents

industry and this shortage is likely to continue. As a result, competition among numerous companies, academic and other research institutions for skilled
personnel and experienced scientists is intense and turnover rates are high. The cost of living in the San Francisco Bay Area is very high compared to other parts of the country, which may adversely affect our ability to compete for qualified
personnel and will increase costs. Because of this competitive environment, we have encountered and may continue to encounter increasing difficulty in attracting qualified personnel as our operations expand and the demand for these professionals
increases and this difficulty could significantly impede the achievement of our research and development objectives.

If physicians and patients do not
accept products that we may develop, our ability to generate product revenue in the future will be adversely affected.

Products that we
may develop may not gain market acceptance among physicians, healthcare payors, patients and the medical community. Market acceptance of and demand for any products that we may develop will depend on many factors, including the following:



| |  |  | our ability to provide acceptable evidence of safety and efficacy;
| | - |  | ------------------------------------------------------------------



| |  |  | convenience and ease of administration;
| | - |  | ---------------------------------------



| |  |  | cost effectiveness;
| | - |  | -------------------



| |  |  | the effectiveness of our marketing strategy and the pricing of any products that we may develop;
| | - |  | ------------------------------------------------------------------------------------------------



| |  |  | our ability to obtain third-party coverage or reimbursement; and
| | - |  | ----------------------------------------------------------------



| |  |  | the prevalence and severity of adverse side effects.
| | - |  | ----------------------------------------------------

Physicians may elect not to recommend products that we may develop even if our products meet the above criteria. If any product that we may develop fails to achieve market acceptance, we may not be able to successfully market and sell that
product, which would limit our ability to generate revenue and adversely affect our operations.

If we or our licensees cannot obtain and defend our
respective intellectual property rights, or if our product candidates, technologies or any products that we may develop are found to infringe patents of third parties, we could become involved in lengthy and costly legal proceedings that could
adversely affect our business.

Our success will depend in a large part on our own and our licensees ability to obtain and defend
patents for each partys respective technologies and the compounds and other products, if any, resulting from the application of these technologies. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and
involve complex legal and factual questions. As a result, the degree of future protection for our proprietary rights is uncertain, and we cannot assure you that:



| |  |  | we were the first to make the inventions covered by each of our pending patent applications;
| | - |  | --------------------------------------------------------------------------------------------



| |  |  | we were the first to file patent applications for these inventions;
| | - |  | -------------------------------------------------------------------



| |  |  | others will not independently develop similar or alternative technologies or duplicate any of our technologies;
| | - |  | ---------------------------------------------------------------------------------------------------------------



| |  |  | any of our pending patent applications will result in issued patents;
| | - |  | ---------------------------------------------------------------------



| |  |  | any patents issued to us or our collaborators will provide a basis for commercially viable products, will provide us with any competitive advantages or will not be challenged by
third parties;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | any of our issued patents will be valid or enforceable; or
| | - |  | ----------------------------------------------------------



| |  |  | we will develop additional proprietary technologies that are patentable.
| | - |  | ------------------------------------------------------------------------

Accordingly, we cannot predict the breadth of claims allowed in our or other companies patents.

For
TRAP, we hold patents in the United States and internationally, including a pending foreign application. These patents, and any patent that may issue on the pending application, will expire between 2014 and 2015. For TELCYTA, we hold compound
patents in the United States and internationally, including a pending foreign application. These patents, and any patent that may issue on the pending application, will expire in 2013 and 2014. For TELINTRA, we hold compound patents in the United
States and internationally, including a pending foreign application. These patents, and any patent that may issue on the pending



26



---

##### Table of Contents

application, will expire in 2014. We can generally apply for patent term extensions on the patents for TELCYTA and TELINTRA when and if marketing approvals
for these compounds are obtained in the relevant countries.

Our success will also depend, in part, on our ability to operate without
infringing the intellectual property rights of others. We cannot assure you that our activities will not infringe patents owned by others. As of the date of this quarterly report, we have not received any communications with the owners of related
patents alleging that our activities infringe their patents. However, if our product candidates, technologies or any products that we may develop are found to infringe patents issued to third parties, the manufacture, use and sale of any products
that we may develop could be enjoined, and we could be required to pay substantial damages. In addition, we may be required to obtain licenses to patents or other proprietary rights of third parties. We cannot assure you that any licenses required
under any such patents or proprietary rights would be made available on terms acceptable to us, if at all. Failure to obtain such licenses could negatively affect our business.

Others may have filed and in the future may file patent applications covering small molecules or therapeutic products that are similar to ours. We cannot
assure you that our patent applications will have priority over patent applications filed by others. Any legal action against us or our collaborators claiming damages and seeking to enjoin commercial activities relating to the affected products and
processes could, in addition to subjecting us to potential liability for damages, require us or our collaborators to obtain a license to continue to manufacture or market the affected products and processes. We cannot predict whether we, or our
collaborators, would prevail in any of these actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. We believe that there may be significant litigation in the industry
regarding patent and other intellectual property rights. If we become involved in litigation, it could consume a substantial portion of our managerial and financial resources, and we may not be successful in any such litigation.

In addition, we could incur substantial costs and use of our key employees time and efforts in litigation if we are required to defend against
patent suits brought by third parties or if we initiate these suits, and we cannot predict whether we would be able to prevail in any of these suits.

Furthermore, some of our patents and intellectual property rights are owned jointly by us and our collaborators. While there are legal and contractual restraints on the rights of these joint owners, they may use these
patents and other intellectual property in ways that may harm our business. We may not be able to prevent this type of use.

We also rely
on trade secrets to protect technology, including aspects of our TRAP technology, where we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. While we require employees, academic
collaborators and consultants to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by
others of such information. If the identity of specific proteins or other elements of our TRAP technology become known, our competitive advantage in drug discovery could be reduced.

Many of our collaborators and scientific advisors have publication and other rights to certain information and data gained from their collaborations and
research with us. Any publication or other use could limit our ability to secure intellectual property rights or impair any competitive advantage that we may possess or realize by maintaining the confidentiality of that information or data.

We will depend on collaborative arrangements to complete the development and commercialization of some of our product candidates. These collaborative
arrangements may place the development of our product candidates outside of our control, may require us to relinquish important rights or may otherwise not be on terms favorable to us.

We expect to enter into collaborative arrangements with third parties for clinical trials, development, manufacturing, regulatory approvals or
commercialization of some of our product candidates, particularly



27



---

##### Table of Contents

outside North America, or in disease areas requiring larger and longer clinical trials. Dependence on collaborative arrangements will subject us to a number
of risks. We may not be able to control the amount and timing of resources our collaborative partners may devote to the product candidates. Our collaborative partners may experience financial difficulties. Should a collaborative partner fail to
develop or commercialize a compound or product candidate to which it has rights from us, we may not receive any future milestone payments and will not receive any royalties for that compound or product candidate. Business combinations or significant
changes in a collaborative partners business strategy may also adversely affect a partners willingness or ability to complete its obligations under an arrangement. If we fail to enter into additional collaborative agreements on favorable
terms, our business, financial condition and results of operations could be materially adversely affected.

Some of our collaborations are
for early stage programs and allow partners significant discretion in electing whether to pursue any of the planned activities. We do not anticipate significant revenues to result from these relationships until the collaborator has advanced product
candidates into clinical trials, which will not occur for several years, if at all. These arrangements are subject to numerous risks, including the right of the collaboration partner to control the timing of the research and development efforts, the
advancement of lead product candidates to clinical trials and the commercialization of product candidates. In addition, a collaborative partner could independently move forward with a competing lead candidate developed either independently or in
collaboration with others, including our competitors.

If we are unable to enter into or maintain existing contracts with third parties to manufacture
our product candidates or any products that we may develop in sufficient quantities and at an acceptable cost, clinical development of product candidates could be delayed and we may be unable to meet demand for any products that we may develop and
lose potential revenue.

We do not currently operate manufacturing facilities for clinical or commercial production of our product
candidates. We expect to continue to rely on third parties for the manufacture of our product candidates and any products that we may develop. We currently lack the resources and capability to manufacture any of our product candidates on a clinical
scale or any products that we may develop on a commercial scale. As a result, we will be dependent on corporate partners, licensees or other third parties for the manufacturing of clinical and commercial scale quantities of our product candidates
and any products that we may develop. Our product candidates and any products that we may develop may be in competition with other product candidates and products for access to these facilities. For this and other reasons, our collaborators or third
parties may not be able to manufacture these product candidates and products in a cost effective or timely manner. While we currently possess sufficient inventory of TELCYTA and TELINTRA that are stored in multiple locations and an additional,
substantial quantity of the active ingredient in TELCYTA, if these inventories are lost or damaged, the clinical development of our product candidates or their submission for regulatory approval could be delayed, and our ability to deliver any
products that we may develop on a timely basis could be impaired or precluded.

We are currently dependent on a single source of supply of
the active ingredient in TELCYTA, Organichem Corporation. While we have entered into an agreement with, and are working to qualify, an additional supplier, there is no certainty this will occur. We currently depend upon two sources for the drug
product manufacture of TELCYTA.

We currently depend upon two sources of supply for clinical quantities of the active ingredient in
TELINTRA. We depend upon a single source of supply for key excipients used in the manufacture of TELINTRA, Lipoid GmbH. While we are evaluating potential alternative sources of these materials, we have no such alternative sources that are
immediately available. We currently depend upon two sources for the drug product manufacture of TELINTRA.

If manufacturing is not
performed in a timely manner, if our suppliers fail to perform or if our relationships with our suppliers or manufacturers should terminate, our clinical trials and commercialization of TELCYTA and TELINTRA could be delayed. We may not be able to
enter into or maintain any necessary third-party manufacturing arrangements on acceptable terms, if at all. Our current dependence upon others for the manufacture of our product candidates and our anticipated dependence upon others for the
manufacture of any products that we may develop may adversely affect our future profit margins and our ability to commercialize any products that we may develop on a timely and competitive basis.



28



---

##### Table of Contents

If we are unable to create sales, marketing and distribution capabilities or enter into agreements with third parties
to perform these functions, we will not be able to commercialize any products that we may develop.

We currently have no sales,
marketing or distribution capabilities. In order to commercialize any products that we may develop, we must internally develop sales, marketing and distribution capabilities or establish collaborations or other arrangements with third parties to
perform these services. We intend to market some products that we may develop directly in North America and rely on relationships with one or more pharmaceutical companies with established distribution systems and direct sales forces to market other
products that we may develop and address other markets. We may not be able to establish in-house sales and distribution capabilities or relationships with third parties. To the extent that we enter into co-promotion or other licensing arrangements,
any product revenues are likely to be lower than if we directly marketed and sold any products that we may develop, and any revenues we receive will depend upon the efforts of third parties, whose efforts may not be successful.

Budget constraints may force us to delay our efforts to develop certain product candidates in favor of developing others, which may prevent us from commercializing
all product candidates as quickly as possible.

Because we have limited resources, and because research and development is an expensive
process, we must regularly assess the most efficient allocation of our research and development budget. As a result, we may have to prioritize development candidates and may not be able to fully realize the value of some of our product candidates in
a timely manner, as they will be delayed in reaching the market, if at all.

If product liability lawsuits are successfully brought against us, we may
incur substantial liabilities and may be required to limit commercialization of our product candidates and any products that we may develop.

The testing and marketing of medical products entail an inherent risk of product liability. Although we are not aware of any historical or anticipated product liability claims or specific causes for concern, if we cannot successfully defend
ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates and any products that we may develop. In addition, product liability claims may also result in
withdrawal of clinical trial volunteers, injury to our reputation and decreased demand for any products that we may commercialize. We currently carry product liability insurance that covers our clinical trials up to a $10 million annual aggregate
limit. We will need to increase the amount of coverage if and when we have a product that is commercially available. If we are unable to obtain sufficient product liability insurance at an acceptable cost, potential product liability claims could
prevent or inhibit the commercialization of any products that we may develop, alone or with corporate collaborators.

If we use biological and hazardous
materials in a manner that causes injury, we may be liable for damages.

Our research and development activities involve the controlled
use of potentially harmful biological materials, hazardous materials, chemicals and various radioactive compounds, and are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials
and specified waste products. We cannot eliminate the risk of accidental contamination or injury from the use, storage, handling or disposal of these materials. We currently have several coverages applying to various types of biological and
pollution exposures for a total amount of $350,000 in insurance, which we believe is a reasonably adequate amount to insulate us from damage claims arising from our use of hazardous materials. However, in the event of contamination or injury, we
could be held liable for damages that result, and any liability could significantly exceed our coverage and resources.



29



---

##### Table of Contents

We have implemented anti-takeover provisions which could discourage or prevent a takeover, even if an acquisition
would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.

Provisions of our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third-party to acquire us, even if doing so would be beneficial to our stockholders.
In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of
directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:



| |  |  | establishing a classified board of directors requiring that members of the board be elected in different years, which lengthens the time needed to elect a new majority of the board;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | authorizing the issuance of blank check preferred stock that could be issued by our board of directors to increase the number of outstanding shares or change the balance
of voting control and thwart a takeover attempt;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | prohibiting cumulative voting in the election of directors, which would otherwise allow for less than a majority of stockholders to elect director candidates;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | limiting the ability of stockholders to call special meetings of the stockholders;
| | - |  | ----------------------------------------------------------------------------------



| |  |  | prohibiting stockholder action by written consent and requiring all stockholder actions to be taken at a meeting of our stockholders; and
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------



| |  |  | establishing 90 to 120 day advance notice requirements for nominations for election to the board of directors and for proposing matters that can be acted upon by stockholders at
stockholder meetings.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We adopted a stockholder rights plan that may discourage, delay or prevent a merger or acquisition that is
beneficial to our stockholders.

In November 2001, our board of directors adopted a stockholder rights plan that may have the effect of
discouraging, delaying or preventing a merger or acquisition that is beneficial to our stockholders by diluting the ability of a potential acquiror to acquire us. Pursuant to the terms of our plan, when a person or group, except under certain
circumstances, acquires 20% or more of our outstanding common stock or 10 business days after commencement or announcement of a tender or exchange offer for 20% or more of our outstanding common stock, the rights (except those rights held by the
person or group who has acquired or announced an offer to acquire 20% or more of our outstanding common stock) would generally become exercisable for shares of our common stock at a discount. Because the potential acquirors rights would not
become exercisable for our shares of common stock at a discount, the potential acquiror would suffer substantial dilution and may lose its ability to acquire us. In addition, the existence of the plan itself may deter a potential acquiror from
acquiring us. As a result, either by operation of the plan or by its potential deterrent effect, mergers and acquisitions of us that our stockholders may consider in their best interests may not occur.

Substantial future sales of our common stock by us or by our existing stockholders could cause our stock price to fall.*

Additional equity financings or other share issuances by us, including shares issued in connection with strategic alliances, could adversely affect the
market price of our common stock. Sales by existing stockholders of a large number of shares of our common stock in the public market or the perception that additional sales could occur could cause the market price of our common stock to drop. As of
March 31, 2006, 52,253,223 shares of our common stock were outstanding, of which 51,945,940 shares were freely tradable and 307,283 shares were transferable in accordance with certain volume, notice and manner of sale restrictions under Rule
144 of the Securities Act of 1933.

If we do not progress in our programs as anticipated, our stock price could decrease.

For planning purposes, we estimate the timing of a variety of clinical, regulatory and other milestones, such as when a certain product candidate will
enter clinical development, when a clinical trial will be



30



---

##### Table of Contents

completed or when an application for regulatory approval will be filed. Some of our estimates are included in this quarterly report. Our estimates are based
on present facts and a variety of assumptions. Many of the underlying assumptions are outside of our control. If milestones are not achieved when we estimated that they would be, investors could be disappointed, and our stock price may decrease.

Our stock price may be volatile, and you may not be able to resell your shares at or above your purchase price.*

Our stock prices and the market prices for securities of biotechnology companies in general have been highly volatile, with recent significant price and
volume fluctuations, and may continue to be highly volatile in the future. During the first three months of 2006, our common stock traded between $22.70 and $16.46. You may not be able to sell your shares quickly or at the market price if trading in
our stock is not active or the volume is low. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of our common stock, some of which are beyond our control:



| |  |  | developments regarding, or the results of, our clinical trials, including TELCYTA clinical trials;
| | - |  | --------------------------------------------------------------------------------------------------



| |  |  | announcements of technological innovations or new commercial products by our competitors or us;
| | - |  | -----------------------------------------------------------------------------------------------



| |  |  | developments concerning proprietary rights, including patents;
| | - |  | --------------------------------------------------------------



| |  |  | developments concerning our collaborations; publicity regarding actual or potential medical results relating to products under development by our competitors or us;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | regulatory developments in the United States and foreign countries;
| | - |  | -------------------------------------------------------------------



| |  |  | litigation;
| | - |  | -----------



| |  |  | economic and other external factors or other disaster or crisis; or
| | - |  | -------------------------------------------------------------------



| |  |  | period-to-period fluctuations in our financial results.
| | - |  | -------------------------------------------------------

We are
required to recognize expense for stock based compensation related to employee stock options and employee stock purchases, and there is no assurance that the expense we are required to recognize measures accurately the value of our share-based
payment awards, and the recognition of this expense could cause the trading price of our common stock to decline.

On January 1,
2006, we adopted SFAS 123R which requires the measurement and recognition of compensation expense for all share-based compensation based on estimated fair values. As a result, our operating results for the first quarter of 2006 and for future
periods will contain a charge for share-based compensation related to employee stock options and employee stock purchases. The application of SFAS 123R requires the use of an option-pricing model to determine the fair value of share-based payment
awards. This determination of fair value is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over
the term of the awards, and actual and projected employee stock option exercise behaviors. Option-pricing models were developed for use in estimating the value of traded options that have no vesting or hedging restrictions and are fully
transferable. Because our employee stock options have certain characteristics that are significantly different from traded options, and because changes in the subjective assumptions can materially affect the estimated value, in managements
opinion the existing valuation models may not provide an accurate measure of the fair value of our employee stock options. Although the fair value of employee stock options is determined in accordance with SFAS 123R and SAB 107 using an
option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction.

We
expect that our adoption of SFAS 123R will have a material impact on our financial statements and results of operations and this will continue to be the case for future periods. We cannot predict the effect that this adverse impact on our reported
operating results will have on the trading price of our common stock.



31



---

##### Table of Contents

Item 6. Exhibits.



|     |  |                                                                                                                                                                                                                      
|---- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|3.1  |  | Amended and Restated Certificate of Incorporation. (1)                                                                                                                                                               
|     | 
|3.2  |  | Amended and Restated Bylaws. (1)                                                                                                                                                                                     
|     | 
|4.1  |  | Specimen Stock Certificate. (1)                                                                                                                                                                                      
|     | 
|4.2  |  | Amended and Restated Registration Rights Agreement, dated March 31, 2000, between Telik and holders of Teliks Series B, Series E, Series F, Series G, Series H, Series I, Series J and
Series K preferred stock. (1)
|     | 
|4.3  |  | Right Agreement dated November 2, 2001, by and between Telik and Wells Fargo Bank Minnesota, N.A., replaced by EquiServe Trust Company, N.A., as Rights Agent. (2)                                                   
|     | 
|4.4  |  | Teliks Certificate of Designation of Series A Junior Participating Preferred Stock. (2)                                                                                                                             
|     | 
|31.1 |  | Certification required by Rule 13a-14(a) or Rule 15d-14(a).                                                                                                                                                          
|     | 
|31.2 |  | Certification required by Rule 13a-14(a) or Rule 15d-14(a).                                                                                                                                                          
|     | 
|32.1 |  | Certifications required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350).                                                                   

---

|(1) | Incorporated by reference to exhibits to our Registration Statement on Form S-1 filed on April 4, 2000, as amended (File No. 333-33868).
|--- | ----------------------------------------------------------------------------------------------------------------------------------------

|(2) | Incorporated by reference to exhibits to our Current Report on Form 8-K dated November 2, 2001 filed on November 5, 2001 (File No. 000-31265).
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------



32



---

##### Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.



TELIK, INC./s/ CYNTHIA M. BUTITTACynthia M. ButittaChief Operating Officer and Chief Financial Officer(Duly Authorized Officer and Principal Financial Officer)


Date: May 5, 2006



33



---

##### Table of Contents

EXHIBIT INDEX



|     |  |                                                                                                                                                                                                                      
|---- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|3.1  |  | Amended and Restated Certificate of Incorporation. (1)                                                                                                                                                               
|     | 
|3.2  |  | Amended and Restated Bylaws. (1)                                                                                                                                                                                     
|     | 
|4.1  |  | Specimen Stock Certificate. (1)                                                                                                                                                                                      
|     | 
|4.2  |  | Amended and Restated Registration Rights Agreement, dated March 31, 2000, between Telik and holders of Teliks Series B, Series E, Series F, Series G, Series H, Series I, Series J and
Series K preferred stock. (1)
|     | 
|4.3  |  | Right Agreement dated November 2. 2001, by and between Telik and Wells Fargo Bank Minnesota, N.A., replaced by EquiServe Trust Company, N.A., as Rights Agent. (2)                                                   
|     | 
|4.4  |  | Teliks Certificate of Designation of Series A Junior Participating Preferred Stock. (2)                                                                                                                             
|     | 
|31.1 |  | Certification required by Rule 13a-14(a) or Rule 15d-14(a).                                                                                                                                                          
|     | 
|31.2 |  | Certification required by Rule 13a-14(a) or Rule 15d-14(a).                                                                                                                                                          
|     | 
|32.1 |  | Certifications required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350).                                                                   

---

|(1) | Incorporated by reference to exhibits to our Registration Statement on Form S-1 filed on April 4, 2000, as amended (File No. 333-33868).
|--- | ----------------------------------------------------------------------------------------------------------------------------------------

|(2) | Incorporated by reference to exhibits to our Current Report on Form 8-K dated November 2, 2001 filed on November 5, 2001 (File No. 000-31265).
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------



34